PreDx has created a groundbreaking class of bioresponsive contrast agents (BCAs), revolutionizing the gene therapy industry by offering real-time, non-invasive monitoring of gene expression in living organisms. Our proprietary MR probes can detect repaired or inserted gene expression products and produce measurable changes in contrast, thereby providing invaluable insights into biodistribution and activity levels of your gene therapies. Importantly, our technology negates the need for sacrificing animals to gauge treatment distribution, a breakthrough with ethical and longitudinal advantages.

Even as the gene therapy market grows, challenges persist, particularly in efficacy evaluation and safety monitoring, areas where PreDx's technology can offer unparalleled advantages:

Risk Mitigation: Early-stage confirmation of gene expression, its efficiency, and spatial distribution could significantly reduce the uncertainties involved in gene therapy development.

Cost-Effectiveness: By enabling real-time imaging and 3D mapping of transgene expression, PreDx's BCAs can considerably cut both time and costs, especially in high-value primate studies where you can reduce the number of animals needed.

Enhanced R&D Capabilities: Our BCAs can easily adapt to monitor multiple enzymes or other targets, offering a versatile tool that can accelerate Caribou BioSciences’ already robust research initiatives.

Data Integrity: Our technology allows for longitudinal studies on the same animal, ensuring data consistency and reducing variables that might skew your results.

PreDx, Inc

Org chart

Teams

Offices